Case Reports

Pediatric Primary Cutaneous Blastomycosis Clinically Responsive to Itraconazole

Author and Disclosure Information

Primary cutaneous blastomycosis is a rare infection, especially among children. We present the case of a 16-year-old immunocompetent adolescent boy with primary cutaneous blastomycosis arising after falling into a flowerbed in a region where the fungus Blastomyces dermatitidis is hyperendemic. Following treatment with itraconazole 200 mg 3 times daily for 3 days, followed by 200 mg 2 times daily for 6 months, the lesion healed with only residual dyschromia.

Practice Points

  • Cutaneous blastomycosis can occur by dissemination of yeast to the skin from systemic and pulmonary disease or rarely via direct inoculation of the skin, resulting in primary cutaneous disease.
  • Exposures often are associated with recreational and occupational activities near streams or rivers where there may be decaying vegetation.
  • Oral itraconazole for 6 to 12 months is the treatment of choice for mild to moderate cutaneous disease.
  • Increased awareness of this rare infection, particularly in geographic areas where its reported incidence is on the rise, could be helpful in reducing delays in diagnosis and treatment.


 

References

Blastomycosis is a polymorphic disease caused by the thermally dimorphic fungus Blastomyces dermatitidis, which is naturally occurring worldwide but particularly prominent in the Great Lakes, Mississippi, and Ohio River areas of the United States. The disease was first described by Thomas Caspar Gilchrist in 1894 and historically has been referred to as Gilchrist disease, North American blastomycosis, or Chicago disease.1,2 Cutaneous blastomycosis can occur by dissemination of yeast to the skin from systemic and pulmonary disease or rarely via direct inoculation of the skin resulting in primary cutaneous disease. Clinically, the lesions are polymorphic and may appear as well-demarcated verrucous plaques containing foci of pustules or ulcerations. Lesions typically heal centrifugally with a cribriform scar.3

We describe an adolescent with a unique history of inoculation 2 weeks prior to the development of a biopsy-confirmed lesion of cutaneous blastomycosis on the left chest wall that clinically resolved following 6 months of itraconazole.

Case Report

A 16-year-old adolescent boy with a history of morbid obesity, asthma, and seasonal allergies presented for evaluation of a painful, slowly enlarging skin lesion on the left chest wall of 2 months’ duration. According to the patient, a “small pimple” appeared at the site of impact 2 weeks following a fall into a muddy flowerbed in Madison, Wisconsin. The patient recalled that although he had soiled his clothing, there was no identifiable puncture of the skin. Despite daily application of hydrogen peroxide and a 1-week course of trimethoprim-sulfamethoxazole, the lesion gradually enlarged. Complete review of systems as well as exposure and travel history were otherwise negative.

Physical examination revealed a 5.0×2.5-cm exophytic, firm, well-circumscribed plaque with a papillated crusted surface on the left side of the chest near the posterior axillary line (Figure 1). There was no palpable regional lymphadenopathy. Pulmonary examination was unremarkable. Diagnostic workup, including complete blood cell count with differential, hemoglobin A1c, human immunodeficiency virus antibody/antigen testing, interferon-gamma release assay, and chest radiograph were all within normal limits.

Figure 1. A 5.0×2.5-cm, slowly growing, oval, exophytic, firm plaque with crusted papillated surface on the left side of the chest presenting 2 months following a fall into a flowerbed.

Histologic examination of a biopsy specimen showed pseudoepitheliomatous hyperplasia of the epidermis with a brisk mixed inflammatory infiltrate (Figure 2). Displayed in Figure 3 is the Grocott-Gomori methenamine-silver stain that highlighted the thick double-contoured wall-budding yeasts.

Figure2

Figure 2. High-power view showed pseudoepitheliomatous hyperplasia of the epidermis associated with a brisk mixed inflammatory infiltrate (H&E, original magnification ×40).

Figure3

Figure 3. Grocott-Gomori methenamine-silver stain revealed thick double-contoured wall-budding yeasts, one of which is depicted in the marked central aspect of the micrograph (red arrow)(original magnification ×40).

The patient was diagnosed with primary cutaneous blastomycosis. Treatment was initiated with itraconazole 200 mg 3 times daily for 3 days, followed by 200 mg 2 times daily for 6 months. Following 3 months of therapy, the lesion had markedly improved with violaceous dyschromia and no residual surface changes. After 5 months of itraconazole, the patient stopped taking the medication for 2 months due to pharmacy issues and then resumed. After 6 total months of therapy, the lesion healed with only residual dyschromia and itraconazole was discontinued.

Pages

Recommended Reading

Dupilumab positive in phase 3 study for treating adolescent atopic dermatitis
MDedge Dermatology
FDA approves Seysara for treatment of moderate to severe acne
MDedge Dermatology
Adalimumab safety profile similar in children and adults
MDedge Dermatology
What is your diagnosis?
MDedge Dermatology
Pediatric Skin Care: Survey of the Cutis Editorial Board
MDedge Dermatology
Hemorrhagic Crusted Papule on the Arm
MDedge Dermatology
Pediatric Dermatology Workforce Shortage Explained
MDedge Dermatology
Acrokeratoelastoidosis and Knuckle Pads Coexisting in a Child
MDedge Dermatology
Hand-foot-and-mouth Disease Caused by Coxsackievirus A6 on the Rise
MDedge Dermatology
Acute Hemorrhagic Edema of Infancy: Guide to Prevent Misdiagnosis
MDedge Dermatology